BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

Inrebic (fedratinib) is the second JAK inhibitor to be approved for myelofibrosis since Incyte’s Jakafi (ruxolitinib) was cleared by the FDA in 2011, and the first new treatment for the ... JAK1/2 inhibitor Jakafi is currently the only FDA-approved

J&J’s targeted bladder cancer treatment gets US approval

Despite the first-to-market personalised medicine claim for FGFR in bladder cancer, J&J could soon be joined by Incyte, which has its own oral FGFR inhibitor, Pemigatinib, in phase ... Incyte are also reviewing their candidate in advanced/metastatic or

Combined immunotherapies – potential and pitfalls

The recent failed phase 3 trial of a combination of MSD’s monoclonal antibody Keytruda (pembrolizumab) and InCyte Corporation’s epacadostat in metastatic melanoma is a case in point he says.

CML-Life Patient Support Programme

Incyte listened to what we had to say, and developed something that we’ll actually use. ... CML-Life Patient Support Programme - by Incyte Biosciences with support from The EarthWorks (an Open Health Company).

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]